{"id":2646,"date":"2019-10-30T19:07:31","date_gmt":"2019-10-30T23:07:31","guid":{"rendered":"http:\/\/localhost:10028\/whitepapers\/hunter-shkolnik-quoted-on-tevas-agreement-proposal\/"},"modified":"2022-06-27T02:34:24","modified_gmt":"2022-06-27T06:34:24","slug":"hunter-shkolnik-quoted-on-tevas-agreement-proposal","status":"publish","type":"whitepapers","link":"https:\/\/napolilaw.lemonadestand.org\/zh\/%e7%99%bd%e7%9a%ae%e4%b9%a6\/hunter-shkolnik-quoted-on-tevas-agreement-proposal\/","title":{"rendered":"Hunter Shkolnik \u5f15\u7528 Teva \u7684\u534f\u8bae\u63d0\u6848"},"content":{"rendered":"<p>J&amp;J, Teva offer a massive\u00a0$48B combined to wrap opioid suits, but not all plaintiffs are on board<\/p>\n<p>With reports like that in the ether, it\u2019s no wonder some plaintiffs are\u00a0reticent to sign on to the \u201cframework deal\u201d that includes the\u00a0Teva and J&amp;J offers, along with\u00a0additional deals with three drug distributors.<\/p>\n<p>Officials in at least four states have\u00a0pushed back\u00a0against the proposal, arguing that Teva\u2019s agreement is \u201covervalued to make the settlement look better,\u201d Hunter Shkolnik, a lawyer on a plaintiffs executive committee, told Reuters.<\/p>","protected":false},"excerpt":{"rendered":"<p>J&amp;J \u548c Teva \u63d0\u4f9b\u4e86\u4e00\u4e2a\u5de8\u5927\u7684 $48B \u7ec4\u5408\u6765\u5305\u88f9\u963f\u7247\u7c7b\u836f\u7269\u5957\u88c5\uff0c\u4f46\u5e76\u975e\u6240\u6709\u539f\u544a\u90fd\u5728\u8239\u4e0a\u6709\u4e86\u8fd9\u6837\u7684\u62a5\u9053\uff0c\u96be\u602a\u4e00\u4e9b\u539f\u544a\u4fdd\u6301\u6c89\u9ed8\u2026\u2026<\/p>","protected":false},"featured_media":0,"menu_order":237,"template":"","whitepaper_category":[75,98,253,254,57],"whitepaper-source":[326],"class_list":["post-2646","whitepapers","type-whitepapers","status-publish","hentry","whitepaper_category-opioids-litigation","whitepaper_category-ohio-opioid-lawyers","whitepaper_category-opioid-crisis","whitepaper_category-opioid-epidemic","whitepaper_category-hunter-shkolnik","whitepaper-source-fiercepharma-com"],"acf":[],"_links":{"self":[{"href":"https:\/\/napolilaw.lemonadestand.org\/zh\/wp-json\/wp\/v2\/whitepapers\/2646","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/napolilaw.lemonadestand.org\/zh\/wp-json\/wp\/v2\/whitepapers"}],"about":[{"href":"https:\/\/napolilaw.lemonadestand.org\/zh\/wp-json\/wp\/v2\/types\/whitepapers"}],"version-history":[{"count":0,"href":"https:\/\/napolilaw.lemonadestand.org\/zh\/wp-json\/wp\/v2\/whitepapers\/2646\/revisions"}],"wp:attachment":[{"href":"https:\/\/napolilaw.lemonadestand.org\/zh\/wp-json\/wp\/v2\/media?parent=2646"}],"wp:term":[{"taxonomy":"whitepaper_category","embeddable":true,"href":"https:\/\/napolilaw.lemonadestand.org\/zh\/wp-json\/wp\/v2\/whitepaper_category?post=2646"},{"taxonomy":"whitepaper-source","embeddable":true,"href":"https:\/\/napolilaw.lemonadestand.org\/zh\/wp-json\/wp\/v2\/whitepaper-source?post=2646"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}